SOHO Annual Meeting 2023
The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) was held on September 6–9, 2023 in Houston, Texas. This year’s meeting focused the latest advances in the pathophysiology and therapy of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, related malignancies, and exciting developments in cellular therapy. The conference included general sessions, meet-the-professor sessions, plenary lectures, expert sessions, oral abstracts, and other interactive and informal exchanges.
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
Limited diagnostic resources, such as EPO level tests, can result in late or misdiagnosis and increased health care costs.
The average cost of hospitalization for a TE was $4000-9000 higher than for generally medically ill patients.
Investigators noted improved spleen size and blood parameters in addition to improvement in PV symptoms.
Rusfertide improved response maintenance and reduced the need for therapeutic phlebotomy.
Advertisement
Advertisement
